IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

M. Jotte, Robert; Cappuzzo, Federico; Vynnychenko, Ihor; Stroyakovskiy, Daniil; Rodríguez‐Abreu, Delvys; Hussein, Maen; A. Soo, Ross; Jacob Conter, Henry; Kozuki, Toshiyuki; Alberto da Silva, Carlos; Graupner, Vilma; W. Sun, Shawn; Lin, Ray; Kelsch, Claudia; Kowanetz, Marcin; Hoang, Tien; N. Sandler, Alan; A. Socinski, Mark

doi:10.1200/jco.2018.36.18_suppl.lba9000

Public

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Shared by NobleBlocks on Jun 7, 2018 • 12:00 AM UTC

Authors:

Robert M. Jotte

Federico Cappuzzo

Ihor Vynnychenko

Abstract

LBA9000 Background: Atezolizumab (atezo; anti–PD-L1) demonstrated OS benefit vs docetaxel in 2L+ NSCLC regardless of PD-L1 status or tumor histology. Because cytotoxic agents can exhibit positive immunomodulatory effects, combining atezo with chemotherapy may further improve outcomes. IMpower131 (NC...

Subject

Medicine

Carboplatin

Atezolizumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!